August Troendle Sells 49,018 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 49,018 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the sale, the chief executive officer owned 433,372 shares in the company, valued at $272,205,286.92. This trade represents a 10.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Medpace Stock Performance

Shares of NASDAQ:MEDP traded down $13.04 during trading on Wednesday, hitting $617.15. The company’s stock had a trading volume of 272,881 shares, compared to its average volume of 333,111. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The business has a 50 day moving average price of $589.62 and a two-hundred day moving average price of $513.16. The company has a market capitalization of $17.22 billion, a PE ratio of 36.18, a P/E/G ratio of 2.78 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on MEDP shares. Robert W. Baird increased their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research report on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Finally, Mizuho upped their price target on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $595.20.

Institutional Trading of Medpace

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after purchasing an additional 28,666 shares during the period. The Manufacturers Life Insurance Company lifted its stake in Medpace by 38.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock valued at $10,615,000 after buying an additional 5,610 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in shares of Medpace by 8.2% in the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company’s stock valued at $587,000 after acquiring an additional 84 shares during the period. Tidal Investments LLC grew its position in shares of Medpace by 8.0% during the second quarter. Tidal Investments LLC now owns 6,155 shares of the company’s stock worth $3,260,000 after acquiring an additional 458 shares during the last quarter. Finally, Archford Capital Strategies LLC grew its position in shares of Medpace by 5.4% during the second quarter. Archford Capital Strategies LLC now owns 1,658 shares of the company’s stock worth $878,000 after acquiring an additional 85 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc is a global contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology and medical device companies. The company supports sponsors throughout the drug and medical product development process, from early-stage planning and clinical trial design through study execution, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.